Kris Deprince

2.0k total citations · 2 hit papers
15 papers, 1.2k citations indexed

About

Kris Deprince is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kris Deprince has authored 15 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kris Deprince's work include Bladder and Urothelial Cancer Treatments (7 papers), Prostate Cancer Treatment and Research (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Kris Deprince is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Prostate Cancer Treatment and Research (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Kris Deprince collaborates with scholars based in United States, Japan and United Kingdom. Kris Deprince's co-authors include Kim N., Vahid Naini, Hirotsugu Uemura, Neeraj Agarwal, Álvaro Juárez Soto, Andrea Juliana Gomes, Mustafa Özgüroğlu, Robert Given, Dingwei Ye and Axel S. Merseburger and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Kris Deprince

13 papers receiving 1.1k citations

Hit Papers

Apalutamide for Metastatic, Castration-Sensitive Prostate... 2019 2026 2021 2023 2019 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    2019 891 citations Kim N., Neeraj Agarwal et al. New England Journal of Medicine profile →
  2. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
    2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kris Deprince United States 7 948 333 312 252 174 15 1.2k
Álvaro Juárez Soto Spain 8 1.1k 1.1× 379 1.1× 345 1.1× 222 0.9× 87 0.5× 44 1.2k
Vahid Naini United States 8 1.1k 1.1× 417 1.3× 357 1.1× 244 1.0× 81 0.5× 21 1.2k
Maria De Santis Austria 9 1.2k 1.3× 474 1.4× 253 0.8× 288 1.1× 153 0.9× 25 1.4k
Sharon McCarthy United States 8 962 1.0× 341 1.0× 326 1.0× 217 0.9× 53 0.3× 28 1.1k
Andrea Juliana Gomes United States 8 1.4k 1.5× 496 1.5× 450 1.4× 336 1.3× 78 0.4× 24 1.5k
Martin Boegemann Germany 19 1.2k 1.2× 630 1.9× 388 1.2× 430 1.7× 147 0.8× 90 1.4k
S. Chowdhury United Kingdom 16 699 0.7× 242 0.7× 291 0.9× 267 1.1× 75 0.4× 58 951
S. Polyakov Belarus 8 811 0.9× 273 0.8× 281 0.9× 180 0.7× 86 0.5× 20 940
Erik Briers Belgium 5 1.1k 1.2× 445 1.3× 223 0.7× 233 0.9× 92 0.5× 7 1.3k
Iris Kuss Germany 12 1.1k 1.2× 400 1.2× 400 1.3× 251 1.0× 53 0.3× 40 1.3k

Countries citing papers authored by Kris Deprince

Since Specialization
Citations

This map shows the geographic impact of Kris Deprince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris Deprince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris Deprince more than expected).

Fields of papers citing papers by Kris Deprince

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris Deprince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris Deprince. The network helps show where Kris Deprince may publish in the future.

Co-authorship network of co-authors of Kris Deprince

This figure shows the co-authorship network connecting the top 25 collaborators of Kris Deprince. A scholar is included among the top collaborators of Kris Deprince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kris Deprince. Kris Deprince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Daneshmand, Siamak, Renata Zaucha, James W.F. Catto, et al.. (2025). Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 89(2). 165–173.
2.
3.
Matsubara, Nobuaki, Yuji Miura, Hiroyuki Nishiyama, et al.. (2024). Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations. International Journal of Clinical Oncology. 29(10). 1516–1527. 3 indexed citations
4.
Loriot, Yohann, Nobuaki Matsubara, Se Hoon Park, et al.. (2023). Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 389(21). 1961–1971. 132 indexed citations breakdown →
5.
6.
7.
Loriot, Yohann, Nobuaki Matsubara, Se Hoon Park, et al.. (2023). Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).. Journal of Clinical Oncology. 41(17_suppl). LBA4619–LBA4619. 25 indexed citations
8.
Uemura, Hirotsugu, Hirotsugu Uemura, Gaku Arai, et al.. (2020). Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study. International Journal of Urology. 28(3). 280–287. 12 indexed citations
9.
10.
Agarwal, Neeraj, Kelly McQuarrie, Anders Bjartell, et al.. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. The Lancet Oncology. 20(11). 1518–1530. 69 indexed citations
11.
12.
13.
N., Kim, Neeraj Agarwal, Anders Bjartell, et al.. (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 381(1). 13–24. 891 indexed citations breakdown →
14.
Fizazi, Karim, NamPhuong Tran, Luis Fein, et al.. (2018). Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.. Journal of Clinical Oncology. 36(6_suppl). 182–182. 7 indexed citations
15.
Deprince, Kris, et al.. (2000). Genetic syndromes and genetic tests in colorectal cancer.. PubMed. 11(4). 207–18. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Álvaro Juárez Soto Breakdown of academic impact, for papers by Vahid Naini Breakdown of academic impact, for papers by Maria De Santis Breakdown of academic impact, for papers by Sharon McCarthy Breakdown of academic impact, for papers by Andrea Juliana Gomes Breakdown of academic impact, for papers by Martin Boegemann Breakdown of academic impact, for papers by S. Chowdhury Breakdown of academic impact, for papers by S. Polyakov Breakdown of academic impact, for papers by Erik Briers Breakdown of academic impact, for papers by Iris Kuss
Rankless by CCL
2026